Navigation Links
New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
Date:2/24/2009

EXTON, Pa., Feb. 24 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends(TM): Uloric(R). Takeda Pharmaceutical Company Limited announced that they received FDA approval for Uloric(R) (generic name: febuxostat) on February 13, 2009. Uloric(R) is indicated for the chronic management of hyperuricemia associated with gout and represents the first product for gout that has been approved in over forty years.

LaunchTrends(TM): Uloric(R) is a three wave primary market research study that consists of a quantitative on-line survey and qualitative telephone interviews. In total, 300 Rheumatologists and Primary Care Physicians will participate in the research. Following a baseline report, three additional waves will be published capturing launch effectiveness at one month, three months, and six months post launch. The reports are designed to assess trial and use of Uloric(R), obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other agents.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
2. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
3. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
4. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
5. Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
6. MannKind Reports Successful Completion of Device Bioequivalence Trial
7. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Pharmasset Reports Fiscal Year End 2008 Financial Results
10. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... nutrition division of Diplomat Specialty Infusion Group, is celebrating a decade of ... To celebrate its anniversary, ThriveRx recently launched a redesigned website at ... organization to create the best user experience for consumers and health care ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 ...
(Date:7/5/2017)... July 5, 2017   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade cell and tissue ... media ("BioLife"), today announced that it has reached an ... and largest shareholder, to modify its existing credit facility ... the modification, WAVI agreed to exchange its existing $4.25 ...
(Date:6/30/2017)... 29, 2017  Axium Pharmaceuticals Inc. is a pharmaceutical company aimed ... and alternative dosage forms of existing biologically active molecule. ... ... waterless self-nano emulsifying formula, which is designed to prevent precipitation ... the spray will provide fast onset of action and is ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know ... nor would a pharmacist using that same scale to dispense medication. The first example ... , These illustrations show why it is important to have the right balance for ...
(Date:7/24/2017)... BEACH, Calif. (PRWEB) , ... July 24, 2017 , ... ... ranging from food addiction to sexual abuse, and how she has overcome them. “Forbidden ... traumatic instances in her life and how she has risen above. , In “Memories,” ...
(Date:7/24/2017)... ... July 24, 2017 , ... Right ... future. , The agency is hammering out a game plan to implement changes ... laws ever to affect FDA-regulated firms. The new law:, , ...
(Date:7/24/2017)... ... July 24, 2017 , ... “A Short Walk to the Mailbox”: a ... the creation of published author, Ed Clark. Ed Clark is a church music ... churches as a minister of music and worship leader for over fifty years. ...
(Date:7/23/2017)... , ... July 23, 2017 , ... A 20-year-long ... St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports ... the disease offers very few benefits. , In the cases involved with this ...
Breaking Medicine News(10 mins):